S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer



Status:Recruiting
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:9/2/2018
Start Date:April 2013
End Date:January 2030
Contact:Cara Laubach, MIIM
Email:claubach@swog.org
Phone:2106148808

Use our guide to learn which trials are right for you!

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using
tamoxifen citrate, goserelin acetate, leuprolide acetate, anastrozole, letrozole, or
exemestane, may fight breast cancer by lowering the amount of estrogen the body makes.
Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. It is not yet know whether hormone therapy is more effective when given with or
without everolimus in treating breast cancer.

PURPOSE: This randomized phase III trial studies how well giving hormone therapy together
with or without everolimus work in treating patients with breast cancer.

OBJECTIVES:

Primary

- To compare whether the addition of one year of everolimus (10 mg daily) to standard
adjuvant endocrine therapy improves invasive disease-free survival (IDFS) in patients
with high-risk, hormone-receptor (HR)-positive, and human epidermal growth factor
receptor (HER)2-negative breast cancer.

Secondary

- To compare whether the addition of one year of everolimus to standard adjuvant endocrine
therapy improves overall survival (OS) and distant recurrence-free survival (DRFS) in
this patient population.

- To evaluate the safety, toxicities, and tolerability of one year of everolimus in
combination with standard adjuvant endocrine therapy and to compare it with standard
adjuvant endocrine therapy plus placebo in this patient population.

- To determine whether the benefit of one year of everolimus use in addition to standard
adjuvant endocrine therapy varies by recurrence score (RS), nodal status, or other
commonly used prognostic factors.

- To evaluate adherence to 1-year treatment of everolimus in comparison to placebo in
addition to standard adjuvant endocrine therapy in this patient population.

- To collect specimens in order to evaluate biomarkers of therapeutic efficacy.
(exploratory)

OUTLINE: This is a multicenter study. Patients are stratified according to risk level
(node-negative and recurrence score [RS] > 25 in the primary tumor, and a tumor measuring ≥ 2
cm in greatest diameter treated with adjuvant therapy vs 1-3 positive lymph nodes and RS > 25
treated with adjuvant therapy vs ≥ 4 positive lymph nodes [any RS value] treated with
adjuvant therapy vs ≥ 4 positive lymph nodes [any RS value] prior to or after neoadjuvant
chemotherapy). Patients are randomized to 1 of 2 treatment arms.

- Arm I: Patients receive an approved endocrine therapy comprising tamoxifen citrate*,
goserelin acetate** or leuprolide acetate**, or aromatase inhibitor (anastrozole,
letrozole, or exemestane) for 2-5 years. Patients also receive a placebo orally (PO)
daily for 1 year in the absence of disease progression or unacceptable toxicity.

- Arm II: Patients receive an approved endocrine therapy regimen as in arm I. Patients
also receive everolimus PO daily for 1 year in the absence of disease progression or
unacceptable toxicity.

NOTE: *Men receive tamoxifen citrate PO for 5 years.

NOTE: **Goserelin acetate or leuprolide acetate is given if patient is or becomes
postmenopausal.

Blood and tissue samples are collected for biomarker studies.

After completion of study treatment, patients are followed up every 6 months for 2 years and
then yearly thereafter for 10 years.

DISEASE CHARACTERISTICS:

- Patients must have a histologically confirmed diagnosis of invasive breast carcinoma
with positive estrogen (ER)- and/or progesterone-receptor (PR) status, and negative
human epidermal growth factor receptor (HER)2, for whom standard adjuvant endocrine
therapy is planned

- ER and PR positivity must be assessed according to American Society of Clinical
Oncology (ASCO)/College of American Pathologists (CAP) guidelines as either ER or
PR ≥ 1% positive nuclear staining

- HER2 test result negativity must be assessed as per ASCO/CAP 2013 guidelines
using IHC, ISH or both.

HER2 is negative if a single test (or all tests) performed in a tumor specimen show:

1. IHC negative (0 or 1+)

2. ISH negative using single probe or dual probe. If IHC is 2+, evaluation for gene
amplification (ISH) must be performed and the ISH must be negative; ISH is not
required if IHC is 0 or 1+.

HER2 equivocal is not eligible.

- Patients must not have metastatic breast cancer (stage IV disease); patients with
multifocal, multicentric, and synchronous bilateral, and primary inflammatory breast
cancers are allowed

- Multifocal disease is defined as more than one invasive cancer < 2 cm from the
largest lesion within the same breast quadrant

- Multicentric disease is defined as more than one invasive cancer ≥ 2 cm from the
largest lesion within the same breast quadrant or more than one lesion in
different quadrants

- Synchronous bilateral disease is defined as invasive breast cancer with positive
lymph nodes (axillary or intramammary) in at least one breast, diagnosed within
30 days of each other

- Patients must be high risk by belonging to one of the following risk groups:

- Completion of adjuvant chemotherapy and pathologically negative axillary nodes,
and a tumor measuring ≥ 2 cm in greatest diameter, and an Oncotype DX® recurrence
score (RS) > 25 (completed as standard of care). Patients with micrometastases as
the only nodal involvement (pN1mi) are eligible, and will be categorized as
node-negative.

- Completion of adjuvant chemotherapy, and pathologically 1-3 positive lymph nodes,
and either an Oncotype DX® RS > 25 (screened via S1007 or otherwise) or tumor
tissue with pathological Grade III following local practice. If Oncotype DX is
done, then RS must be > 25. If the test is not done, but the patient has Grade
III disease then the patient is eligible and Oncotype DX does not need to be
performed.

- Completion of adjuvant chemotherapy and pathologically 4 or more positive lymph
nodes.

- Completion of neoadjuvant chemotherapy and 1 or more positive nodes
pathologically determined prior to or after chemotherapy

- Patients must have completed either breast-conserving surgery or total mastectomy,
with negative margins and appropriate axillary staging; a negative margin is defined
as no evidence of tumor or ductal carcinoma in situ (DCIS) at the line of resection;
additional operative procedures may be performed to obtain clear margins

- Patients who had breast-conserving surgery must have completed whole-breast
radiation; use of regional nodal-basin radiation will be at the discretion of the
investigator according to institutional guidelines

- Patients with ≥ 4 positive lymph nodes must have completed breast/chest wall and
nodal-basin radiation therapy according to standard-of-care guidelines before
randomization; omission of radiation therapy is not allowed in this high-risk
population of patients

- Patients must be registered no sooner than 21 days after completion of radiation
therapy and must have recovered (≤ grade 1) from any of the effects of radiation

- Patients must have undergone axillary staging by sentinel-node biopsy or axillary
lymph node dissection (ALND)

- For patients with 1-3 positive lymph nodes, sentinel-node biopsy alone is allowed
provided that the patient completed either whole-breast or chest-wall radiation
and the primary tumor is < 5 cm

- All patients with ≥ 4 positive lymph nodes must have completed ALND (with or
without prior sentinel-node biopsy)

PATIENT CHARACTERISTICS:

- Absolute Neutrophil Count ≥ 1,500/mL

- Hemoglobin ≥ 9 g/dL

- Platelet count ≥ 100,000/mL

- Bilirubin ≤ 1.5 mg/dL (≤ 3.0 mg/dL if due to Gilbert syndrome)

- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 1.5 times
institutional upper limit of normal (IULN)

- Alkaline phosphatase ≤ 1.5 times IULN

- Serum creatinine level ≤ IULN

- Fasting cholesterol ≤ 300 mg/dL and triglycerides ≤ 2.5 times IULN; patients may be on
lipid-lowering agents to reach these values

- Patients must have a performance status of 0-2 by Zubrod criteria

- Patients must not have any grade III/IV cardiac disease as defined by the New York
Heart Association Criteria (i.e., patients with cardiac disease resulting in marked
limitation of physical activity or resulting in inability to carry on any physical
activity without discomfort), unstable angina pectoris, myocardial infarction within 6
months, or serious uncontrolled cardiac arrhythmia

- Patients previously diagnosed with diabetes must not have uncontrolled diabetes
(defined as a hemoglobin [Hg] A1C > 7% within 28 days prior to registration)

- Patients known to be human immunodeficiency virus (HIV) positive may be enrolled if
baseline CD4 count is > 500 cells/mm³ and they are not taking anti-retroviral therapy

- Patients with known hepatitis are not eligible

- Patients must not have any known uncontrolled, underlying pulmonary disease

- Patients must be able to take oral medications

- Patients may not have any impairment of gastrointestinal function or gastrointestinal
disease that may significantly alter the absorption of blinded drug (e.g., ulcerative
disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small
bowel resection)

- Patients must not be pregnant or nursing

- Women/men of reproductive potential must have agreed to use an effective non-hormonal
contraceptive method during and for 8 weeks after completion of study therapy

- In addition to routine contraceptive methods, "effective contraception" also
includes heterosexual celibacy and surgery intended to prevent pregnancy (or with
a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral
oophorectomy, or bilateral tubal ligation; corresponding procedures for men
include castration, vasectomy, and barrier-contractive devices

- If at any point a previously celibate patient chooses to become heterosexually
active during the protocol therapy, he/she is responsible for beginning
contraceptive measures

- No other prior malignancy is allowed except for adequately treated basal cell or
squamous cell skin cancer, in situ cervical cancer, or other cancer for which the
patient has been disease-free for 5 years

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- Patients must have completed standard neoadjuvant or adjuvant chemotherapy prior to
randomization; completion of chemotherapy will be determined by the treating
oncologist, but should include a minimum of 4 cycles (a cycle of weekly paclitaxel is
considered 3 doses); patients must be registered within 42 weeks after the last dose
of chemotherapy; patients may have started endocrine therapy at any time after the
diagnosis of the current breast cancer

- Patients must not be receiving or planning to receive trastuzumab

- Concurrent bisphosphonate therapy is allowed

- Patients must not have prior exposure to mTOR inhibitors (rapamycin, everolimus,
temsirolimus, deforolimus)

- Patients must not have prior treatment with any investigational drug within the
preceding 28 days and must not be planning to receive any other investigational drug
for the duration of the study

- Patients must not be planning to receive any other anticancer drug for the duration of
the study

- Patients must not have an organ allograft or other history of immune compromise;
patients must not be receiving chronic, systemic treatment with corticosteroids or
other immunosuppressive agent; topical or inhaled corticosteroids are allowed

- Patients must not have received immunization with an attenuated live vaccine (e.g.,
intranasal influenza, measles, mumps, and rubella [MMR], oral polio, varicella,
zoster, yellow fever, and Bacillus Calmette-Guérin [BCG] vaccines) within seven days
prior to registration nor have plans to receive such vaccination while on protocol
treatment

- Patients must not have taken within 14 days prior to registration, be taking, nor plan
to take while on protocol treatment, strong cytochrome P450 3A4 (CYP3A4) inhibitors
and/or CYP3A4 inducers
We found this trial at
1455
sites
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
(505) 272-4946
Principal Investigator: Ursa A. Brown-Glaberman
Phone: 505-925-0366
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
361 Old Belgrade Road
Augusta, Maine 04330
(207) 621-6100
Principal Investigator: Peter Rubin
Phone: 207-626-4855
Harold Alfond Center for Cancer Care MaineGeneral's Harold Alfond Center for Cancer Care (HACCC) is...
?
mi
from
Augusta, ME
Click here to add this to my saved trials
8600 Old Georgetown Road
Bethesda, Maryland 20814
301-896-3100
Principal Investigator: Antonio C. Wolff
Phone: 301-896-2719
Suburban Hospital Suburban Hospital is a community-based, not-for-profit hospital serving Montgomery County and the surrounding...
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
2545 Schoenersville Rd
Bethlehem, Pennsylvania 18017
(484) 884-2200
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Lehigh Valley Hospital - Muhlenberg At Lehigh Valley Health Network, we continually go the extra...
?
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
?
mi
from
Bremerton, WA
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
1 South Prospect Street
Burlington, Vermont 05401
802-656-8990
Principal Investigator: Marie E. Wood
?
mi
from
Burlington, VT
Click here to add this to my saved trials
1300 Jefferson Park Avenue
Charlottesville, Virginia 22908
434-243-6784
Principal Investigator: Patrick M. Dillon
Phone: 434-243-6303
University of Virginia Cancer Center We are fortunate in having state of the art clinical...
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
3500 Gaston Avenue
Dallas, Texas 75246
1.800.422.9567
Principal Investigator: Joanne L. Blum
Phone: 800-422-9567
Baylor University Medical Center Baylor University Medical Center in Dallas, TX is ranked nationally in...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
1500 E Duarte Rd
Duarte, California 91010
(626) 256-4673
Principal Investigator: James R. Waisman
Phone: 800-826-4673
City of Hope Comprehensive Cancer Center City of Hope is a leading research and treatment...
?
mi
from
Duarte, CA
Click here to add this to my saved trials
1 Hurley Plaza
Flint, Michigan 48503
(810) 262-9000
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
?
mi
from
Flint, MI
Click here to add this to my saved trials
4725 North Federal Highway
Fort Lauderdale, Florida 33308
(954) 771-8000
Principal Investigator: Michael A. Schwartz
Phone: 954-267-7750
Holy Cross Hospital While spirituality plays an essential role in the way that we minister...
?
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
(601) 984-1000
Principal Investigator: Barbara S. Craft
Phone: 601-815-6700
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
?
mi
from
Jackson, MS
Click here to add this to my saved trials
Jupiter, Florida 33458
?
mi
from
Jupiter, FL
Click here to add this to my saved trials
524 South Park Street
Kalamazoo, Michigan 49007
(269) 341-7654
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Methodist Hospital Our healthcare system serves patients and families throughout southwest Michigan and northern...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
1800 West Charleston Boulevard
Las Vegas, Nevada 89102
(702) 383-2000
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
University Medical Center of Southern Nevada University Medical Center is dedicated to providing the highest...
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
529 West Markham Street
Little Rock, Arkansas 72205
(501) 686-7000
Principal Investigator: Issam Makhoul
Phone: 501-686-8274
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
8700 Beverly Blvd # 8211
Los Angeles, California 90048
(1-800-233-2771)
Principal Investigator: Monica M. Mita
Phone: 310-423-8965
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
300 Community Drive
Manhasset, New York 11030
(516) 562-0100
Principal Investigator: Lora R. Weiselberg
Phone: 516-562-3467
North Shore University Hospital North Shore-LIJ Health System includes 16 award-winning hospitals and nearly 400...
?
mi
from
Manhasset, NY
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Gary E. Goodman
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
?
mi
from
Portland, OR
Click here to add this to my saved trials
401 College Street
Richmond, Virginia 23298
(804) 828-0450
Principal Investigator: Harry D. Bear
Phone: 888-823-5923
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
?
mi
from
Richmond, VA
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
(585) 275-2121
Principal Investigator: Paul M. Barr
Phone: 585-275-5830
University of Rochester The University of Rochester is one of the country's top-tier research universities....
?
mi
from
Rochester, NY
Click here to add this to my saved trials
4502 Medical Drive
San Antonio, Texas 78284
(210) 567-7000
Principal Investigator: Kate I. Lathrop
Phone: 210-450-3800
University of Texas Health Science Center at San Antonio The University of Texas Health Science...
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Sarasota, Florida 34236
Principal Investigator: Fadi Kayali
Phone: 941-957-1000
?
mi
from
Sarasota, FL
Click here to add this to my saved trials
825 Eastlake Ave E
Seattle, Washington 98109
(206) 288-7222
Principal Investigator: Julie R. Gralow
Phone: 800-804-8824
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Seattle, Washington 98104
Principal Investigator: Gary E. Goodman
Phone: 206-215-3086
?
mi
from
Seattle, WA
Click here to add this to my saved trials
1100 Fairview Avenue North
Seattle, Washington 98109
(206) 667-5000
Principal Investigator: Julie R. Gralow
Phone: 800-804-8824
Fred Hutchinson Cancer Research Center At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
3900 W Avera Drive
Sioux Falls, South Dakota 57108
(605) 322-4700
Avera Cancer Institute Avera, the health ministry of the Benedictine and Presentation Sisters, is a...
?
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
601 South Sherman Street
Spokane, Washington 99202
(509) 228-1000
Principal Investigator: Julie R. Gralow
Phone: 509-228-1680
Cancer Care Northwest - Spokane South Cancer Care Northwest is the Inland Northwest’s premier cancer...
?
mi
from
Spokane, WA
Click here to add this to my saved trials
808 North 39th Avenue
Yakima, Washington 98902
Principal Investigator: John A. Keech
Phone: 509-574-3535
?
mi
from
Yakima, WA
Click here to add this to my saved trials
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-487-7447
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
98-1079 Moanalua Road
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-486-6000
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
2226 Liliha Street
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-678-9000
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
Aberdeen, South Dakota 57401
?
mi
from
Aberdeen, SD
Click here to add this to my saved trials
Aberdeen, Washington 98520
Principal Investigator: Gary E. Goodman
Phone: 360-412-8958
?
mi
from
Aberdeen, WA
Click here to add this to my saved trials
1200 Old York Road
Abington, Pennsylvania 19001
(215) 481–2000
Principal Investigator: Willard G. Andrews
Phone: 215-481-2402
Abington Memorial Hospital Abington Memorial Hospital (AMH) is a 665-bed, regional referral center and teaching...
?
mi
from
Abington, PA
Click here to add this to my saved trials
Adrian, Michigan 49221
?
mi
from
Adrian, MI
Click here to add this to my saved trials
818 Riverside Ave.
Adrian, Michigan 49221
(517) 265-0900
Bixby Medical Center ProMedica's Mission is to improve your health and well-being. Which is why,...
?
mi
from
Adrian, MI
Click here to add this to my saved trials
?
mi
from
Akron, OH
Click here to add this to my saved trials
1 Akron General Avenue
Akron, Ohio 44307
Principal Investigator: Esther H. Rehmus
Phone: 866-223-8100
?
mi
from
Akron, OH
Click here to add this to my saved trials
Albany, Georgia 31701
Principal Investigator: Sharad A. Ghamande
Phone: 229-312-0405
?
mi
from
Albany, GA
Click here to add this to my saved trials
Albuquerque, New Mexico 87102
Principal Investigator: Ursa A. Brown-Glaberman
Phone: 505-272-0530
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Albuquerque, New Mexico 87106
Principal Investigator: Melanie E. Royce
Phone: 505-272-6972
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Albuquerque, New Mexico 87109
Principal Investigator: Ursa A. Brown-Glaberman
Phone: 505-272-0530
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Albuquerque, New Mexico 87110
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Albuquerque, New Mexico 87102
Principal Investigator: Ursa A. Brown-Glaberman
Phone: 505-272-0530
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Alexandria, Louisiana 71301
Principal Investigator: John T. Cole
Phone: 318-448-6976
?
mi
from
Alexandria, LA
Click here to add this to my saved trials
Allentown, Pennsylvania 18103
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
?
mi
from
Allentown, PA
Click here to add this to my saved trials
Altamonte Springs, Florida 32701
Principal Investigator: Carlos A. Alemany
Phone: 888-823-5923
?
mi
from
Altamonte Springs, FL
Click here to add this to my saved trials
Amarillo, Texas 79106
Principal Investigator: Brian T. Pruitt
Phone: 806-212-1985
?
mi
from
Amarillo, TX
Click here to add this to my saved trials
170 North 1100 East
American Fork, Utah 84003
Principal Investigator: Xylina T. Gregg
Phone: 801-408-1347
?
mi
from
American Fork, UT
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Joseph J. Merchant
Phone: 515-239-2621
?
mi
from
Ames, IA
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Joseph J. Merchant
Phone: 515-239-2621
?
mi
from
Ames, IA
Click here to add this to my saved trials
Anaconda, Montana 59711
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
?
mi
from
Anaconda, MT
Click here to add this to my saved trials
Anacortes, Washington 98221
Principal Investigator: Gary E. Goodman
Phone: 206-386-2323
?
mi
from
Anacortes, WA
Click here to add this to my saved trials
Anaheim, California 92806
Principal Investigator: Han A. Koh
Phone: 800-398-3996
?
mi
from
Anaheim, CA
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 98508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99504
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
2000 E Greenville St
Anderson, South Carolina 29621
(864) 512-4640
Principal Investigator: James D. Bearden
Phone: 800-486-5941
AnMedical Health Cancer Center Cancer is the general term for a group of more than...
?
mi
from
Anderson, SC
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
800-865-1125
Principal Investigator: Anne F. Schott
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Ann Arbor, Michigan 48106
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Annapolis, Maryland 21401
Principal Investigator: Carol K. Tweed
Phone: 443-481-1320
?
mi
from
Annapolis, MD
Click here to add this to my saved trials
Antigo, Wisconsin 54409
Principal Investigator: Harish G. Ahuja
Phone: 715-623-9869
?
mi
from
Antigo, WI
Click here to add this to my saved trials
Antioch, California 94531
Principal Investigator: Jennifer M. Suga
Phone: 877-642-4691
?
mi
from
Antioch, CA
Click here to add this to my saved trials
?
mi
from
Appleton, WI
Click here to add this to my saved trials
Ardmore, Oklahoma 73401
Principal Investigator: Soley Bayraktar
Phone: 405-751-4343
?
mi
from
Ardmore, OK
Click here to add this to my saved trials
921 North Oak Park Boulevard
Arroyo Grande, California 93420
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
?
mi
from
Arroyo Grande, CA
Click here to add this to my saved trials
364 White Oak St
Asheboro, North Carolina 27203
(336) 625-5151
Principal Investigator: James M. Granfortuna
Phone: 336-832-0821
Randolph Hospital Since 1932, Randolph Hospital has been fortunate to employ dedicated and loyal personnel...
?
mi
from
Asheboro, NC
Click here to add this to my saved trials
Asheville, North Carolina 28801
Principal Investigator: Cameron B. Harkness
Phone: 800-506-2550
?
mi
from
Asheville, NC
Click here to add this to my saved trials
Asheville, North Carolina 28801
Principal Investigator: Cameron B. Harkness
Phone: 828-213-4150
?
mi
from
Asheville, NC
Click here to add this to my saved trials
Asheville, North Carolina 28801
Principal Investigator: Cameron B. Harkness
Phone: 828-213-4150
?
mi
from
Asheville, NC
Click here to add this to my saved trials
Asheville, North Carolina 28803
Principal Investigator: Raymond Thertulien
Phone: 828-681-2917
?
mi
from
Asheville, NC
Click here to add this to my saved trials
Asheville, North Carolina 28816
Principal Investigator: Cameron B. Harkness
Phone: 828-213-4150
?
mi
from
Asheville, NC
Click here to add this to my saved trials
Ashland, Kentucky 41101
Principal Investigator: David K. Goebel
Phone: 888-823-5923
?
mi
from
Ashland, KY
Click here to add this to my saved trials
1625 Maple Lane
Ashland, Wisconsin 54806
Principal Investigator: Bret E. Friday
Phone: 218-786-3308
?
mi
from
Ashland, WI
Click here to add this to my saved trials
1615 Maple Lane
Ashland, Wisconsin 54806
Principal Investigator: Bret E. Friday
?
mi
from
Ashland, WI
Click here to add this to my saved trials
Athens, Georgia 30607
Principal Investigator: Sharad A. Ghamande
Phone: 706-353-5006
?
mi
from
Athens, GA
Click here to add this to my saved trials
Attleboro, Massachusetts 02703
Principal Investigator: Asma Latif
Phone: 508-236-7059
?
mi
from
Attleboro, MA
Click here to add this to my saved trials
Auburn, California 95602
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
?
mi
from
Auburn, CA
Click here to add this to my saved trials
Auburn, California 95603
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
?
mi
from
Auburn, CA
Click here to add this to my saved trials
Auburn, New York 13021
Principal Investigator: Jeffrey J. Kirshner
Phone: 315-472-7504
?
mi
from
Auburn, NY
Click here to add this to my saved trials
Auburn, Washington 98001
Principal Investigator: John A. Keech
Phone: 253-887-9333
?
mi
from
Auburn, WA
Click here to add this to my saved trials
Augusta, Georgia 30912
Principal Investigator: Sharad A. Ghamande
Phone: 706-721-2388
?
mi
from
Augusta, GA
Click here to add this to my saved trials
Aurora, Colorado 80012
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Aurora, CO
Click here to add this to my saved trials
1501 S Potomac St
Aurora, Colorado 80012
(303) 695-2600
Principal Investigator: Keren Sturtz
Phone: 888-785-6789
Medical Center of Aurora At The Medical Center of Aurora and Centennial Medical Plaza patients...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
12605 East 16th Avenue
Aurora, Colorado 80045
720-848-0000
Principal Investigator: Anthony D. Elias
Phone: 720-848-0650
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
(630) 978-6200
Principal Investigator: Maria T. Grosse-Perdekamp
Phone: 630-978-6212
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
?
mi
from
Aurora, IL
Click here to add this to my saved trials
1500 Red River Street
Austin, Texas 78701
Principal Investigator: Om N. Pandey
Phone: 512-324-7991
?
mi
from
Austin, TX
Click here to add this to my saved trials
Aventura, Florida 33180
Principal Investigator: Michael A. Schwartz
Phone: 888-823-5923
?
mi
from
Aventura, FL
Click here to add this to my saved trials
Bainbridge Island, Washington 98110
Principal Investigator: John A. Keech
Phone: 206-342-6954
?
mi
from
Bainbridge Island, WA
Click here to add this to my saved trials
3325 Pocahontas Road
Baker City, Oregon 97814
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
?
mi
from
Baker City, OR
Click here to add this to my saved trials
Bakersfield, California 93301
Principal Investigator: Helen K. Chew
Phone: 916-734-3089
?
mi
from
Bakersfield, CA
Click here to add this to my saved trials